Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
D 23.26 -2.06% -0.49
RGNX closed down 2.06 percent on Monday, February 6, 2023, on approximately normal volume. It was able to find support at its 50 day moving average.
Earnings due: Feb 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Flat

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Gapped Down Weakness -2.06%
MACD Bullish Signal Line Cross Bullish -3.33%
Pocket Pivot Bullish Swing Setup -3.33%
BB Squeeze Ended Range Expansion -3.33%
Gapped Up Strength -3.33%
Up 3 Days in a Row Strength -3.33%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 7 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
Fell Below 20 DMA about 8 hours ago
20 DMA Support about 8 hours ago
10 DMA Support about 8 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

REGENXBIO Inc. Description

REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Emerging Technologies Molecular Biology Genetics Gene Therapy Medical Genetics Macular Degeneration Cholesterol Applied Genetics Wet Age Related Macular Degeneration Lipoprotein Gene Delivery Hypercholesterolemia Retinitis Adeno Associated Virus Mucopolysaccharidosis Retinitis Pigmentosa Mozy Homozygous Familial Hypercholesterolemia Iduronidase Mucopolysaccharidosis Type Rgx X Linked Retinitis Pigmentosa

Is RGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.72
52 Week Low 18.69
Average Volume 338,872
200-Day Moving Average 25.05
50-Day Moving Average 22.97
20-Day Moving Average 23.22
10-Day Moving Average 23.30
Average True Range 0.98
RSI 50.98
ADX 18.79
+DI 23.00
-DI 16.49
Chandelier Exit (Long, 3 ATRs) 22.59
Chandelier Exit (Short, 3 ATRs) 24.68
Upper Bollinger Bands 24.48
Lower Bollinger Band 21.96
Percent B (%b) 0.52
BandWidth 10.83
MACD Line 0.17
MACD Signal Line 0.13
MACD Histogram 0.039
Fundamentals Value
Market Cap 870.12 Million
Num Shares 37.4 Million
EPS -1.36
Price-to-Earnings (P/E) Ratio -17.12
Price-to-Sales 9.50
Price-to-Book 3.33
PEG Ratio 0.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.31
Resistance 3 (R3) 24.33 24.00 24.14
Resistance 2 (R2) 24.00 23.73 23.99 24.08
Resistance 1 (R1) 23.63 23.57 23.47 23.61 24.02
Pivot Point 23.30 23.30 23.22 23.29 23.30
Support 1 (S1) 22.93 23.03 22.77 22.91 22.50
Support 2 (S2) 22.60 22.87 22.59 22.44
Support 3 (S3) 22.23 22.60 22.39
Support 4 (S4) 22.21